Every 8-K that Applied DNA Sciences, Inc. (APDN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow APDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APDN filings page.
BNB Plus Corp., formerly Applied DNA Sciences, Inc., has officially changed its corporate name effective November 13, 2025, through an amendment to its certificate of incorporation filed in Delaware. The company states that this name change does not affect the rights of its stockholders. Its common stock now trades on The Nasdaq Stock Market under the symbol BNBX, continuing with the same class of common shares and par value. A press release announcing the new name was issued on November 17, 2025 and is provided as an exhibit for additional context.
Applied DNA Sciences appointed Joshua Kruger as Chairman and director effective November 6, 2025, replacing Judith Murrah as Chair; she remains on the Board. The vacancy followed the previously disclosed resignation of Sanford R. Simon on September 29, 2025.
The Board determined Mr. Kruger is not independent under Nasdaq rules. He is affiliated with Cypress Management LLC (Strategic Advisor) and Cypress LLC (Services Provider) and holds an approximately 33% economic interest in each. The Company pays the Strategic Advisor a monthly fee of $60,000 and, in connection with October 2025 private placements, issued five‑year warrants to purchase 1,986,634 shares. Mr. Kruger also purchased 75,302 shares and warrants for an aggregate $250,002.64.
Under the Strategic Digital Assets Services Agreement, the Services Provider earns a management fee of 1.25% per annum (accrued monthly) on Account NAV and an incentive fee of 10% on net returns as defined. The Company will enter its standard indemnification agreement with Mr. Kruger.
Applied DNA Sciences entered an at-the-market offering agreement with Lucid Capital Markets, allowing the company to sell common stock from time to time for an aggregate offering price of up to $8,157,932 under its effective Form S-3 and a prospectus supplement dated November 4, 2025.
Shares may be sold at market prices as defined under Rule 415, with the agent earning a fixed commission of 3.0% on gross sales. The company is not obligated to sell any shares and can suspend or terminate the program. It estimates approximately $175,000 in commencement expenses (excluding agent compensation and reimbursements). The company also agreed to reimburse the agent up to $50,000 for counsel at launch, plus up to $5,000 for certain subsequent filings or amendments, and $2,500 for each Form 10-Q. A legal opinion from McDermott Will & Schulte LLP is included as an exhibit.
Applied DNA Sciences (APDN) closed two previously announced private placements. The Cash Offering sold 4,620,485 shares and/or prefunded warrants at $3.32 per share, together with 4,620,485 Series E-1 warrants exercisable at $3.82 per share. The Cryptocurrency Offering sold 3,444,191 prefunded warrants at $3.32 per warrant and 3,444,191 Series E-2 warrants exercisable at $3.82 per share.
Gross proceeds included $15.3 million in cash and stablecoins and OBNB trust units valued at $11.71 million (as of October 22, 2025). The Company received 0.126 OBNB trust units per prefunded warrant and common warrant, totaling 435,638 trust units that represent underlying ownership of 10,647 BNB tokens.
Applied DNA Sciences announced a corporate restructuring to refocus resources on a BNB-focused treasury strategy. The company will cut its workforce by 16 employees, about 60% of staff, and expects to incur approximately $1.4M of pre-tax charges for severance, benefits, and related costs. Management expects the reduction-in-force to be substantially completed by end of October 2025 and for the charges to be recorded in the first quarter of fiscal 2026. The company estimates the plan will generate annualized cost savings of about $2.9M, but cautions the estimates rely on assumptions and actual amounts may differ materially, including potential additional costs.
Applied DNA Sciences, Inc. (APDN) filed a Form 8-K disclosing a set of exhibits dated September 29, 2025. The filing lists forms of financing and related documents, including cash and cryptocurrency securities purchase agreements, multiple warrant forms (prefunded, common, cryptocurrency, advisory, and placement agent warrants), registration rights agreements, and a Strategic Digital Asset Services Agreement plus a related Strategic Advisor Agreement with Cypress entities. The exhibit list also includes employment and separation agreements, a press release, a supplemental business description, and supplemental risk factors. These exhibits indicate contemporaneous arrangements covering securities issuance mechanics, digital-asset-related services/advisory support, and personnel agreements that could affect corporate structure and capitalization.
Applied DNA Sciences, Inc. entered a three-year consulting and sponsorship arrangement through September 23, 2028, under which a named Consultant will provide advisory and marketing services and deliver premium sponsorship benefits at all SALT conferences globally for 36 months.
The Company will pay the Consultant a total upfront/contracted fee structure including $1,000,000 and additional amounts of $250,000 paid quarterly from December 2025 until September 2027. Immediately following the closing of the referenced Offering, the Consultant will receive warrants exercisable for a number of common shares equal to 1% of the fully diluted outstanding equity of the Company as of immediately after that closing. The Consultant Warrants have an exercise price equal to 115% of the per-share purchase price under the Securities Purchase Agreement, are exercisable for cash for five years, and may be exercised on a cashless basis beginning six months after issuance if resale registration is not available.
The filing is signed by Clay Shorrock, Chief Executive Officer.